发明公开
EP0590489A2 New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
失效
新作用于心脏的Zyklopetnaperhydrophenanthrene-17-β-（羟基或烷氧基）-17-α-（芳基或杂环基）-3-β衍生物，它们的其制备方法和药物制剂的方法。
- 专利标题： New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
- 专利标题（中）： 新作用于心脏的Zyklopetnaperhydrophenanthrene-17-β-（羟基或烷氧基）-17-α-（芳基或杂环基）-3-β衍生物，它们的其制备方法和药物制剂的方法。
-
申请号： EP93115247.4申请日： 1993-09-22
-
公开(公告)号： EP0590489A2公开(公告)日： 1994-04-06
- 发明人: Gobbini, Mauro , Ferrandi, Mara , Frigerio, Marco , Melloni, Piero , Torri, Marco , Valentino, Loredana
- 申请人： Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- 申请人地址： Viale Shakespeare, 47 I-00144 Roma IT
- 专利权人： Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- 当前专利权人： Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- 当前专利权人地址： Viale Shakespeare, 47 I-00144 Roma IT
- 代理机构： Fassi, Aldo
- 优先权： DE4232656 19920929
- 主分类号： C07J41/00
- IPC分类号： C07J41/00 ; C07J43/00 ; A61K31/58
摘要：
Cyclopentanperhydrophenanthren-17-(hydroxy or alkoxy)-17-(aryl or heterocyclyl)-3β-derivatives of general formula (I):
wherein:
the symbol means that the hydrogen in position 5 can have an a or configuration;
the symbol represents either a single or a double bond;
and X, R, R 1 and R 2 have the meanings given in the description;
a process for producing same and their use for the preparation of a medicament for the treatment of cardiavascular disorders such as heart failure and hypertension is disclosed.
wherein:
the symbol means that the hydrogen in position 5 can have an a or configuration;
the symbol represents either a single or a double bond;
and X, R, R 1 and R 2 have the meanings given in the description;
a process for producing same and their use for the preparation of a medicament for the treatment of cardiavascular disorders such as heart failure and hypertension is disclosed.
信息查询
